Background: Mootraghata [benign prostatic hyperplasia (BPH)] is a senile disorder that affects to the people above 40 years of age, having obstructive and irritative symptoms like retention, incomplete voiding, dribbling, hesitancy, incontinence of urine, increased frequency, weak stream, etc. In modern science conservative and surgical both interventions are not free from side effects. So in this age group, there is a need for a safe alternative method of management.
INTRODUCTION
In Ayurvedic classics, Mootraghata gives the symptoms of low urinary output either by retention, absolute or relative anuria or oliguria. Mootraghata is predominantly because of the Vata dosha. 1 The Vata dosha is responsible for expelling the urine output timely and uniformly. If Vata gets vitiated, it causes various diseases related to Basti and produces Mutraroga such as Prameha, Ashmari, Mootraghata, Mutrakruchcha, etc. In Ayurveda, Mootraghata may have some similarity with BPH on the basis of symptoms like Achala unnata granthi (singly movable and elevated gland), Vinmutranilasanga (retention of urine, faeces, and flatus), Bastiadhmana (distension of the urinary bladder), Vedanachaparabastou (excruciating pain in the bladder). 2 The overall incidence rate of BPH is 15 per 1000 men per year. The incidence of BPH is at least 50% for all men at the age of 40 years and above. 3 In India, BPH is common in old age with an incidence of 92.97% (n = 185) and 93.3% (n = 200). 4 In modern medicine, the management of BPH is either by conservative treatment using drugs (e.g., hormonal therapy, chemotherapy, etc.) or through a surgical approach (e.g., open prostatectomy, transurethral resection of prostate-transurethral resection of the prostate (TURP), cryotherapy, etc.). 5 In old age, the surgery is associated with many complications like postoperative morbidity, impotence, retrograde ejaculation, etc. 6 In case of hormonal therapy there are complications like loss of libido, impotency, etc. Basti (Matra basti) is an authentic treatment for vitiated Vayu where no any strict restrictions are required. 7 So, for Vata dosha basti in general and Matra basti in particular, may be helpful in reducing the size of the prostate and enhancing the tone of the urinary bladder. So, the study has been designed with Varuna shigru guggulu orally, and Bala taila matra basti.
AIM AND OBJECTIVES
To evaluate and compare clinical effect of Varuna shigru guggulu and Matra basti of Bala taila with tamsulosin hydrochloride in the management of Mootraghata (BPH).
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MATERIALS AND METHODS
The study design is a randomized control clinical study. 100 patients having signs and symptoms of Mootraghata/ BPH were randomly selected from the outpatient department (OPD) and inpatient department (IPD) of Shalya Tantra Department, Institute for Postgraduate Teaching and Research in Ayurveda Hospital, Jamnagar and randomly divided by draw method into two groups that is A and B (Flow chart 1). The trial formulations Bala taila and Varuna shigru guggulu were procured from Pharmacy of Gujarat Ayurved University, Jamnagar. The standard control drug has been procured from chemist and druggist shop, local market of Jamnagar. Ethical clearance was obtained from the Institutional Ethics Committee (no.PGT/7A/Ethics/2014-15/ 2652, dated 18/12/2014) before the commencement of the study. Informed consent was obtained from each registered patient before starting the treatment. The trial is also registered to Clinical Trial Registry of India (CTRI/2015/10/006279) retrospectively.
Inclusion Criteria
Patients of age above 40 years having signs and symptoms of Mootraghata (BPH) were included in this study.
Exclusion Criteria
Patients below 40 years of age were excluded. Patients suffering from malignancy, systemic diseases like uncontrolled hypertension and diabetes mellitus, tuberculosis, paralysis, and parkinsonism, etc. were excluded from the study.
Grouping and Posology
Group A (Trial group)
Both the trial drugs, Varuna shigru guggulu, and Bala taila (Anubhuta Yoga) are in accordance with schedule Y of D and C Act. Orally: Varuna Shigru Guggulu was administered in a dose of 500 mg, 8 thrice a day for 30 days with lukewarm water, half an hour before breakfast.
Flow Chart 1:
Outflow of the patients in the study Matra basti: Bala taila was administered in dose of 60 ml through rectal route once daily as Matra basti, for 30 days just before breakfast.
Group B (Controlled group)
Orally: Capsule tamsulosin hydrochloride, 0.2 mg twice a day, for 30 days after meal.
Procedure of Matra Basti
In most of the patients, Matra basti was given after getting admitted to Shalya male ward and adopted the standard procedure of Matra basti. 
Criteria for Assesment
The assessment has been made on the basis of subjective parameters with IPSS 10 and adopted as standard objective parameters.
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Statistical Analysis
Student t-test, the unpaired t-test was applied for objective parameters to evaluate the comparative effect of therapy between groups. In case of subjective parameters, the data was analyzed by applying the Wilcoxon sign rank test.
OBSERVATIONS
Total hundred patients completed the treatment and follow-up, 50 patients in each group. Most of the patients in this study (65%) were from the age-group of 61 to 80 years as BPH is a disease related to aging. Fifty-two percent of the patients had chronic ity of BPH more than one year which suggested that slow progressive nature of BPH. Seventy-nine percent of patients were belonging to Vatakaphaja prakriti which is an important risk factor for susceptibility or develop ment of Mootraghata. The symptoms of BPH like noctu ria, increased frequency, dysuria, incomplete voiding, and the weak stream was observed 70% of patients as these are cardinal symptoms of BPH. The per rectal digital examination findings of BPH like smooth surface, upper border approachable, median grove palpable, soft consistency and free rectal mucosa all these signs were observed in 60% patients. These findings are suggestive that the selected patients had the benign enlargement of the prostate and there was no possibility of malignancy.
RESULTS
In group A (trial group), the symptomatic relief in symptoms likes dribbling, dysuria, incomplete voiding, weak stream and increased frequency of micturition was found statistically highly significant (Table 1 ). The insignificant decrease was observed on post-void residual urine volume (Table 2) .
In group B (standard control group) maximum patients showed symptomatic relief in almost all symptoms and statistically found a highly significant result ( Table 3 ). The controlled drug (capsule tamsulosin HCl) rendered statistically highly significant (p <0.001) effect on the size of the enlarged prostate gland. Insignificant (p <0.05) changes were observed in the average urine flow rate and post-void residual urine volume (Table 4) . Statistically insignificant result was seen in all the laboratory investigations in both groups. In case of prostatespecific antigen (PSA) maximum patients showed a mild increase in PSA value before treatment. In patients of group A, PSA value is decreased in some cases while remained same in remaining cases.
In group B, PSA value is not much decreased as compared to group A. Serum testosterone level remained similar in some patients and 50% cases it was improved in group A. In group B, maximum patients (54%) showed decreased serum testosterone level (Tables 5 to 7) .
In subjective parameters, group A had shown a better result, i.e., 75.88% than group B (64.22%). In all objective parameters that are prostate size, PVRU, AUFR, group A patients had shown the better effect by 14.15% than group B (10.55%) ( Table 8) .
There was a statistically significant difference (p <0.001) observed within both groups in subjective parameters. Hence both groups have given a different effect on the IPSS score of disease according to statistical analysis ( Table 9 ).
The comparative effect on objective parameters like prostate size, PVRU volume, and average UFR was calculated by using unpaired t-test. It was found that the difference between A and B (p >0.05) in the size of the prostate which was statistically insignificant. In post-void residual urine and average urine flow rate difference between A and B (p < 0.01) and (p < 0.001) was statistically significant. Hence it can be said that there was no statistical difference in both groups in relieving the prostate size or equally effective. The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant difference between the input groups. So, both groups are working individually in relieving the post-void residual urine and average urine flow rate (Table 10) .
It is evident that completely cured in subjective parameters was seen in four patients (4%), while none BT-Before treatment, AT-After treatment, SD-Standard deviation, SEM-Standard error of mean, MB-Matra basti, VSG-Varun shigru guggulu patients cured in objective parameters. Maximum improvement was noted in 31% of patients in subjective parameters, while none patient in objective parameters.
Moderate improvement was noted in 54% of patients in subjective parameters; while none patient in the objective para-meter. A mild improvement was noted in 9% of patients in subjective parameters; while 13% of patients in the objective parameter. Two percent of patients in subjective parameters while 87% in objective parameters remained unchanged after completion of therapy (Table 11 ).
Overall Effect of Therapies
In group A, the overall effect of the trial drug was found that out of 50 patients, 14 patients, i.e., 28% have shown maximum improvement; 27 patients, i.e., 54% have shown moderate improvement followed by eight patient, i.e., 16% have shown mild improvement after completion of the course. One patient had unchanged after therapy. No patient had shown complete cured (Table 12) . In group B, the overall effect of the controlled drug was found that out of 50 patients, 4 patients, i.e., 8% have shown maximum improvement and 30 patients, i.e., 60% have shown moderate improvement followed by 16 patients i.e., 32% have shown mild improvement after completion of the course. There was none patient in complete cured and unchanged category (Table 13 ).
It was found that out of 100 patients, 18 patients i.e., 18% have shown maximum improvement and 57 patients i.e., 57% have shown moderate improvement followed by 24 patients, i.e., 24% have shown mild improvement after completion of the course. There was one patient unchanged and none patient in the complete cured category (Table 14) . Hence, group A (trial group) showed the better result (65.66%) in overall effect than group B (controlled group), i.e. 56.04% (Table 15 ).
DISCUSSION
The concept of nodular hyperplasia in the pathology of BPH has been established, but its exact cause is still unknown. 12 In fact, the development of BPH is multifactorial phenomenon as there is no substantial evidence for risk factors like smoking, vasectomy, obesity or high alcohol intake for developing clinical features of BPH. 13 The Mootraghata is a broad term and it can be considered as a syndrome, because it covers most of the pathological entity of the urinary system into 12 types.
14 These types may be correlated with three major groups of modern parlance, that is neurogenic bladder disturbances (NBD), bladder outflow obstruction (BOO) and lower urinary tract symptoms (LUTS).
In group A, patients were administered with Varuna shigru guggulu orally, and Bala taila matra basti which had Vatakapha shamak properties because of its Mootrala, Grahee, Pramathee, and Vatakapha shamaka 15 pharmacological actions played a vital role in breaching Samprapti of Mootraghata. The pharmacological studies on Varuna (Crateva nurvala Buch.-Ham.) and Shigru (Moringa 16 In Ayurveda, it is mentioned that Matra basti is the choice of treatment in controlling Vata dosha in all types of Mootraghata. 17 So, it can be said that the function of the detrusor muscle of bladder might be improved by controlling Apana vayu with the help of Matra basti. In this group, a significant result was observed in an average urine flow rate and reduction of prostate size. According to Sushruta, Varuna and Shigru included in Varunadi gana which used in the treatment of Mootraghata. 18 The effect of Matra basti was seen on Apana vayu and effect of the drug was shown as Mootrala and Vatakapha shamaka. Matra basti has also given balya effect to the Basti snayu which helped to improve the tone of the bladder and ultimately resulted in Samprapti vighatana of Vata vriddhi. The insignificant decrease was observed on post-void residual urine volume which might be because of the short duration of therapy and weakness in detrusor muscles generally found in old age.
In group B maximum patients showed symptomatic relief in almost all symptoms and statistically found a highly significant result. The capsule tamsulosin hydrochloride) rendered statistically highly significant (p <0.001) effect on the size of the enlarged prostate gland. In significant (p <0.05) changes were observed in the AUFR and PVRU. Tamsulosin is primarily used for BPH. Tamsulosin is also used as an add-on treatment for acute urinary retention. 19 Tamsulosin is a selec- tive α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. When alpha one receptors in the bladder neck and the prostate are therefore less resistance to urinary flow. Because of this, the pain associated with BPH can be reduced. Selective action of tamsulosin in alpha one A/D receptors is controversial and over three-quarters of tamsulosin registered human studies are unpublished. Tamsulosin hydrochloride is benzene sulfonamide alpha one blocker having some selectivity for alpha one, a subtype as compared to alpha one B. The alpha blockers increase the urinary flow by relaxing this smooth muscle by blocking alpha one receptor. Statistically, the insignificant result was seen in all the laboratory investigations in both groups. In cases of prostate-specific antigen (PSA) maximum patients showed a mild increase in PSA value before treatment. In patients of group A, PSA value is decreased in some cases while remained the same in some cases. This proves that trial drugs Varun shigru guggulu (VSG) and procedure Matra basti controls further progress of the disease. In group B, PSA value is not much decreased as compared to group A. Serum testosterone level remained similar in some patients and 50% cases it was improved in group A, which again verifies the effect of the trial drug in maintaining the hormonal balance. It is scientifically proven that the decline of testosterone level occurred in old age. 20 In group B, maximum patients (54%) showed decreased serum testosterone level.
There was no any untoward effect, or adverse drug reaction (ADR) observed in both groups. General debility, vertigo, hypotension, etc, the side effect was observed in Tamsulosin Hydrochloride 21 while none patient reported such side effect in Ayurved intervention, i.e., Varuna shigru guggulu and Bala taila matra basti (group A).
CONCLUSION
Finally study concluded that VSG and Bala taila Matra Basti (BT-MB) is safe and effective in the symptomatic management of mootraghata (BPH) and better option than tamsulosin hydrochloride.
